Author:
Mohutsky Michael,Hall Stephen D.
Reference118 articles.
1. FDA U Drug development and drug interactions: table of substrates, inhibitors and inducers. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 10 June 2020
2. Rougee LRA, Mohutsky MA, Bedwell DW, Ruterbories KJ, Hall SD (2017) The impact of the hepatocyte-to-plasma pH gradient on the prediction of hepatic clearance and drug-drug interactions for CYP2C9 and CYP3A4 substrates. Drug Metab Dispos 45(9):1008–1018
3. Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FG (2013) Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. Eur J Pharm Sci 49(5):819–828
4. Brown HS, Wilby AJ, Alder J, Houston JB (2010) Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. Drug Metab Dispos 38(12):2139–2146
5. Renton KW (1985) Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 34(14):2549–2553. https://doi.org/10.1016/0006-2952(85)90541-6
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献